Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
the 6 Shrewd Beds for seniors: A Complete Survey - 27 Moves toward a Sound and Dynamic Way of life
- 310 Demonstrated Systems to Develop Your Internet based Business
- 4Medicine doesn’t just have ‘conscientious objectors’ − there are ‘conscientious providers,’ too
- 5Palestinian infant freezes to death in Gaza as Israel keeps blocking aid
- Vote in favor of your Favored Travel Movement
- Addressing sleep apnea early might decrease chances of developing Parkinson's disease
- Journey Travel Objections for Your Next Experience
- Barry Manilow to have surgery for early-stage lung cancer and postpones January concerts
- Fundamental Home Items Each Animal person Needs
- Free Fuel Giveaway Sparks Traffic Mayhem Before Police Shut It Down
- How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
- Carnival fever hits Lagos as locals celebrate Afro-Brazilian heritage
- Saturn shines with the waxing moon at sunset on Nov. 29
